GlassScriptPhysician profile
Robert S Goldblatt
NPI 1568497881
$4,979.97
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,616 · 2020: $1,195 · 2021: $1,770 · 2022: $383 · 2024: $16.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,159.18 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $830.05 | 2019-2022 | |
| Pfizer INC. | $369.14 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $280.97 | 2019-2024 | Trintellix |
| Janssen Biotech, INC. | $251.17 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $188.23 | 2020-2022 | |
| Alfasigma USA, INC. | $176.40 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $174.60 | 2021 | |
| Allergan, INC. | $174.56 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $163.82 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $145.57 | 2019-2021 | |
| Ucb, INC. | $143.37 | 2019 | |
| Ferring Pharmaceuticals INC. | $130.51 | 2019-2020 | |
| Gilead Sciences, INC. | $120.44 | 2019-2021 | |
| Evoke Pharma, INC. | $77.76 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Pharmaceuticals INC. | $74.41 | 2019 | |
| Intra-Sana Laboratories | $67.58 | 2021-2022 | |
| Vivus LLC | $58.52 | 2019-2020 | |
| Esperion Therapeutics, INC. | $56.91 | 2020-2021 | |
| Qol Medical, LLC | $56.45 | 2021 | |
| Intercept Pharmaceuticals, INC. | $43.83 | 2020-2021 | |
| Celgene Corporation | $38.04 | 2021-2022 | |
| Braintree Laboratories, INC. | $31.37 | 2021 | |
| Merck Sharp & Dohme LLC | $28.74 | 2020-2021 | |
| Ethicon US, LLC | $28.05 | 2022 | |
| Daiichi Sankyo INC. | $24.70 | 2019 | |
| Eisai INC. | $22.62 | 2019 | |
| Boston Scientific Corporation | $16.82 | 2019 | |
| Amarin Pharma, INC. | $16.81 | 2019 | |
| Lucid Diagnostics INC. | $15.02 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $14.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goldblatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.